A tiny Swedish biotech's Alzheimer's drug; maternity care 'deserts'

BioArctic licensed lecanemab to Eisai, a Japanese giant, in exchange for hundreds of millions in milestone payments and a "high single digit" royalty. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by   STAT+: For Swedish professor and his tiny biotech, Alzheimer's drug means vindication and a fortune By Jason Mast Courtesy BioArctic A Swedish professor and his company, BioArctic, became millions of dollars wealthier after the results of the lecanemab trial. Read More Maternity care 'deserts' on the rise across the U.S., report finds By Theresa Gaffney Molly Ferguson for STAT A maternity care desert is any county without a hospital or birth center offering obstetric care and without any obstetric providers. Read More STAT+: As small-town telepharmacies struggle to stay open, national chains eye an opportunity By Katie Palmer Molly Ferguson for STAT Telepharmacies that aim to serve small towns are struggling to stay open — and now, national chains like CVS are moving in. Read More Sponsor content by Janssen New IBD treatment data shows efficacy without steroid use Drawing from a two-decades-long legacy of immunology innovation, Janssen is presenting new data at the 2022 United Gastroenterology (UEG) Week on our existing therapy as well as our novel, investigational combination therapies for the treatment of inflammatory bowel disease (IBD). These findings underscore Janssen‘s continued commitment to researching and understanding IBD and its inflammatory pathways, towards the pursuit of therapies that can potentially address the multifaceted nature of these immune-mediated diseases. Learn more about Janssen's latest Immunology data. A minuscule new HHS office has a mammoth goal: tackling environmental justice By Sarah Owermohle Rogelio V. Solis/AP HHS' new environmental justice office has a mammoth charge. But with no money and a staff of just two, can it accomplish anything? Read More STAT+: Bright exits ACA health insurance marketplaces to stay afloat By Bob Herman Adobe Bright Health Group is drastically cutting back its health insurance offerings for next year in an attempt to stay solvent. Read More Opinion: Medicare's cuts to home health are a step in the wrong direction By Terry Wilcox John Moore/Getty Images Medicare has proposed cuts to home health care that could total $18 billion over the next decade, a blow to millions of Americans. Read More U.S. preventive health group recommends anxiety screening for kids 8 to 18 By Usha Lee McFarling Jon Cherry/Getty Images A national survey found that 7.8% of children and teens had a current anxiety disorder — numbers that likely worsened during the pandemic. Read More Opinion: CBO's dismissal of health care price transparency is based on faulty premises By Cynthia A. Fisher Adobe The Congressional Budget Office estimates that hospital price transparency will have a minimal effect. It's based on poor evidence. Read More Tuesday, October 11, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser